Lung cancer trials in France

In France 316 Also abroad 2746

316 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 14 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Where
La Roche Sur Yon Cedex 9, Marseille, Paris, Saint-Herblain, Saint-Herblain Cedex
Age
18 years and over
People
50 worldwide
Run by
Puma Biotechnology, Inc.
See details and how to joinNCT07465757 · EU 2026-525382-47-00
Phase 2/3Taking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Angers, Boulogne-Billancourt, Brest, Caen Cedex 5, Creteil Cedex, Grenoble Cedex 9, Limoges, Lorient, Marseille, Montpellier, Mulhouse, Paris, Saint-Herblain, Saint-Herblain Cedex, Strasbourg Cedex, Tours, Villejuif
Age
18 years and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
Phase 1/2Taking people
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Where
Bordeaux, Lille, Lyon, Marseille, Saint-Herblain Cedex, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
345 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT06043817 · EU 2023-506759-51-00
Phase 3Taking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Avignon, Bron, Créteil, Lille, Lyon, Marseille, Montpellier, Paris, Paris Cedex 20, Pessac, Villejuif
Age
18 years and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
Phase 3Taking people
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Where
Angers, Avignon Cedex 9, La Roche Sur Yon Cedex 9, Marseille, Vantoux
Age
18 years and over
People
851 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Where
Avignon, La Rochelle, Lyon, Nimes Cedex 9, Rennes Cedex 9, Strasbourg Cedex, Suresnes, Toulon Cedex 9
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00
Phase 2Not yet taking people in France
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
Angers, Dijon, Lyon, Marseille, Paris, Poitiers, Saint-Herblain Cedex
Age
18 years and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
Phase 1Taking people
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Where
Bordeaux, Lyon, Pierre-Bénite, Villejuif
Age
18 years and over
People
404 worldwide
Run by
Astellas Pharma Inc
See details and how to joinNCT07094204 · EU 2025-522082-29-00
No phaseNot yet taking people in France
Impact of a Radiologic and Immunologic Signature on Cerebral Efficacy of Treatments in Lung Cancers With Brain Metastasis
Where
Bordeaux
Age
18 years and over
People
38
Run by
University Hospital, Bordeaux
See details and how to joinNCT07904013
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Where
Avignon, La Rochelle, Lyon, Nimes Cedex 9, Rennes Cedex 9, Strasbourg Cedex, Suresnes, Toulon Cedex 9
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00
Phase 1/2Taking people
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
Where
Bordeaux, Dijon, Lille, Marseille, Toulouse, Villejuif
Age
18 years and over
People
235 worldwide
Run by
Alentis Therapeutics AG
See details and how to joinNCT06747585 · EU 2024-515459-39-00
Phase 3Taking people
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
Where
Angers, Avignon
Age
18 years and over
People
390 worldwide
Run by
ETOP IBCSG Partners Foundation
See details and how to joinNCT06931717 · EU 2024-519901-36-00
Phase 1/2Taking people
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Where
Bordeaux, Dijon, Limoges, Marseille, Nice Cedex 2, Paris, Saint-Herblain
Age
18 years and over
People
152 worldwide
Run by
AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01
Phase 1/2Taking people
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Where
Angers, Bordeaux, Dijon, Montpellier, Nice Cedex 2, Paris, Saint-Herblain, Villejuif
Age
18 years and over
People
252 worldwide
Run by
AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00
Phase 3Taking people
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Where
Amiens Cedex 1, Angers, Boulogne-Billancourt, Brest, Caen Cedex 5, Clermont-Ferrand, Dijon, Grenoble Cedex 9, Limoges Cedex 1, Marseille, Montpellier Cedex 5, Mulhouse, Paris, Saint-Herblain, Vandoeuvre Les Nancy, Villejuif
Age
18 years and over
People
630 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Bordeaux, Dijon, Lille, Lyon, Marseille, Nantes, Toulouse, Vandœuvre-lès-Nancy, Villejuif
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
No phaseTaking people
Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis
Where
Besançon, Dijon, Lyon
Age
18 years and over
People
378
Run by
Centre Georges Francois Leclerc
See details and how to joinNCT07376512
Phase 3Taking people
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
Where
Avignon Cedex 9, Bayonne, Besancon Cedex, Bobigny, Brest Cedex 2, Bron, Cholet, Créteil, Grenoble Cedex 9, La Roche Sur Yon Cedex 9, Le Mans Cedex 9, Limoges, Lyon Cedex 04, Marseille, Montpellier Cedex 5, Mulhouse, Nancy Cedex, Paris, Pessac, Pierre-Bénite, Poitiers, Rennes, Saint-Herblain, Saint-Herblain Cedex, Strasbourg Cedex, Toulon Cedex 9, Toulouse, Villejuif
Age
18 years and over
People
340 worldwide
Run by
OSE Immunotherapeutics
See details and how to join2023-509340-10-00
No phaseTaking people
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
Where
Aix-en-Provence, Albi, Amiens, Avignon, Bordeaux, Brest, Créteil, Dijon, Gleizé, Limoges, Lyon, Metz, Nantes, Paris, Pau, Pringy, Quimper, Reims, Rennes, Suresnes, Toulon, Toulouse, Tours, Troyes, TSA 50032 Toulouse, Valenciennes, Vandœuvre-lès-Nancy, Vannes
Age
18 years and over
People
90
Run by
Pfizer
See details and how to joinNCT06487078
Phase 3Taking people
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Where
Angers, Bordeaux, Boulogne-Billancourt, Bron, Creteil Cedex, Dijon, Lille Cedex, Lyon, Marseille, Montpellier, Nantes Cedex 2, Paris, Paris Cedex 20, Saint-Herblain, Toulouse
Age
18 years and over
People
686 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00
Phase 1Taking people
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Where
Saint-Herblain Cedex, Toulouse, Villejuif
Age
18 years and over
People
40 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07140016 · EU 2025-522398-12-00
Phase 3Taking people
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Where
Dijon, Grenoble Cedex 9, Limoges, Nice Cedex 2, Paris, Pessac, Quimper Cedex, Reims, Villefranche Sur Saone Cedex
Age
18 years and over
People
750 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00
Phase 2Taking people
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Where
Marseille, Montpellier, Montpellier Cedex 5, Nice Cedex 2, Paris, Saint-Herblain, Villejuif
Age
18 years and over
People
160 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07680764 · EU 2026-525170-19-00
No phaseTaking people
Cognition and Patients With Lung Cancer
Where
Paris
Age
18 years to 74 years
People
90
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT07160751
Phase 1Not yet taking people in France
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Where
Lyon, Marseille
Age
18 years and over
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-518348-19-00